346 related articles for article (PubMed ID: 22079368)
1. Treatment of osteoporosis in women intolerant of oral bisphosphonates.
Aspray TJ; Francis RM
Maturitas; 2012 Jan; 71(1):76-8. PubMed ID: 22079368
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
3. Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.
Cole RE
Postgrad Med; 2011 Mar; 123(2):131-44. PubMed ID: 21474901
[TBL] [Abstract][Full Text] [Related]
4. Osteoporosis: non-hormonal treatment.
Rizzoli R
Climacteric; 2007 Oct; 10 Suppl 2():74-8. PubMed ID: 17882678
[TBL] [Abstract][Full Text] [Related]
5. [New development in bisphosphonate treatment. Clinical significance of combinatorial therapies with bisphosphonates and parathyroid hormone for osteoporosis].
Takeuchi Y
Clin Calcium; 2009 Jan; 19(1):85-90. PubMed ID: 19122268
[TBL] [Abstract][Full Text] [Related]
6. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Wensel TM; Iranikhah MM; Wilborn TW
Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
[TBL] [Abstract][Full Text] [Related]
7. Fracture prevention in postmenopausal osteoporosis: a review of treatment options.
McCarus DC
Obstet Gynecol Surv; 2006 Jan; 61(1):39-50. PubMed ID: 16359568
[TBL] [Abstract][Full Text] [Related]
8. Patient treatment preferences for osteoporosis.
Fraenkel L; Gulanski B; Wittink D
Arthritis Rheum; 2006 Oct; 55(5):729-35. PubMed ID: 17013870
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of currently marketed anti-osteoporosis medications.
Reginster JY; Neuprez A; Dardenne N; Beaudart C; Emonts P; Bruyere O
Best Pract Res Clin Endocrinol Metab; 2014 Dec; 28(6):809-34. PubMed ID: 25432354
[TBL] [Abstract][Full Text] [Related]
10. Considerations regarding adherence of anti-osteoporosis therapy.
Lagari VS; McAninch E; Baim S
Postgrad Med; 2015 Jan; 127(1):92-8. PubMed ID: 25526234
[TBL] [Abstract][Full Text] [Related]
11. Drug insight: Existing and emerging therapies for osteoporosis.
Mulder JE; Kolatkar NS; LeBoff MS
Nat Clin Pract Endocrinol Metab; 2006 Dec; 2(12):670-80. PubMed ID: 17143314
[TBL] [Abstract][Full Text] [Related]
12. Use of bisphosphonates in the management of postmenopausal osteoporosis.
Papapoulos SE
Ann N Y Acad Sci; 2011 Feb; 1218():15-32. PubMed ID: 20946579
[TBL] [Abstract][Full Text] [Related]
13. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
McHorney CA; Schousboe JT; Cline RR; Weiss TW
Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
[TBL] [Abstract][Full Text] [Related]
14. The relative merits of anabolics versus anti-resorptive compounds: where our targets should be, and whether we are addressing them.
Gasser JA
Curr Opin Pharmacol; 2006 Jun; 6(3):313-8. PubMed ID: 16650802
[TBL] [Abstract][Full Text] [Related]
15. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Ettinger MP
Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
[TBL] [Abstract][Full Text] [Related]
16. Clinical and therapeutic aspects of osteoporosis.
Compston J
Eur J Radiol; 2009 Sep; 71(3):388-91. PubMed ID: 19660883
[TBL] [Abstract][Full Text] [Related]
17. EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis.
Palacios S; Brincat M; Erel CT; Gambacciani M; Lambrinoudaki I; Moen MH; Schenck-Gustafsson K; Tremollieres F; Vujovic S; Rees M; Rozenberg S
Maturitas; 2012 Feb; 71(2):194-8. PubMed ID: 22176952
[TBL] [Abstract][Full Text] [Related]
18. Treatment of osteoporosis with parathyroid hormone and teriparatide.
Pleiner-Duxneuner J; Zwettler E; Paschalis E; Roschger P; Nell-Duxneuner V; Klaushofer K
Calcif Tissue Int; 2009 Mar; 84(3):159-70. PubMed ID: 19189037
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
Cosman F; Borges JL; Curiel MD
Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
[TBL] [Abstract][Full Text] [Related]
20. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]